Listed

Dianthus Therapeutics, Inc.

DNTHNasdaqCIK 1690585HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$284.0k, Q4 FY2025
Operating income−$61.5m, Q2 FY2026
Net income−$50.2m, Q2 FY2026
Dianthus Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.9Revenue, Q3 FY2023, three months to 2023-09-30$924.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure0.5Revenue, Q4 FY2023, three months to 2023-12-31$457.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-037131. Derived: 12-month figure less the 9-month figure.Report this figure0.9Revenue, Q1 FY2024, three months to 2024-03-31$874.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure1.9Revenue, Q2 FY2024, three months to 2024-06-30$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure2.2Revenue, Q3 FY2024, three months to 2024-09-30$2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure1.3Revenue, Q4 FY2024, three months to 2024-12-31$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure1.2Revenue, Q1 FY2025, three months to 2025-03-31$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure0.2Revenue, Q2 FY2025, three months to 2025-06-30$193.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure0.4Revenue, Q3 FY2025, three months to 2025-09-30$396.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure0.3Revenue, Q4 FY2025, three months to 2025-12-31$284.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$m8.0Research and development, Q3 FY2023, three months to 2023-09-30$8.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure8.8Research and development, Q4 FY2023, three months to 2023-12-31$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-11, accession 0000950170-25-037131. Derived: 12-month figure less the 9-month figure.Report this figure13.1Research and development, Q1 FY2024, three months to 2024-03-31$13.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure18.1Research and development, Q2 FY2024, three months to 2024-06-30$18.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure25.5Research and development, Q3 FY2024, three months to 2024-09-30$25.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure26.4Research and development, Q4 FY2024, three months to 2024-12-31$26.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure27.0Research and development, Q1 FY2025, three months to 2025-03-31$27.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure26.3Research and development, Q2 FY2025, three months to 2025-06-30$26.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure32.5Research and development, Q3 FY2025, three months to 2025-09-30$32.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure59.9Research and development, Q4 FY2025, three months to 2025-12-31$59.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure34.5Research and development, Q1 FY2026, three months to 2026-03-31$34.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure48.7Research and development, Q2 FY2026, three months to 2026-06-30$48.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Operating income$m(15.8)Operating income, Q3 FY2023, three months to 2023-09-30−$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure(13.0)Operating income, Q4 FY2023, three months to 2023-12-31−$13.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037131. Derived: 12-month figure less the 9-month figure.Report this figure(17.8)Operating income, Q1 FY2024, three months to 2024-03-31−$17.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure(22.2)Operating income, Q2 FY2024, three months to 2024-06-30−$22.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure(29.9)Operating income, Q3 FY2024, three months to 2024-09-30−$29.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(31.9)Operating income, Q4 FY2024, three months to 2024-12-31−$31.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(33.2)Operating income, Q1 FY2025, three months to 2025-03-31−$33.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(34.9)Operating income, Q2 FY2025, three months to 2025-06-30−$34.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(40.3)Operating income, Q3 FY2025, three months to 2025-09-30−$40.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(69.5)Operating income, Q4 FY2025, three months to 2025-12-31−$69.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(46.5)Operating income, Q1 FY2026, three months to 2026-03-31−$46.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(61.5)Operating income, Q2 FY2026, three months to 2026-06-30−$61.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(14.8)Net income, Q3 FY2023, three months to 2023-09-30−$14.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure(10.6)Net income, Q4 FY2023, three months to 2023-12-31−$10.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-037131. Derived: 12-month figure less the 9-month figure.Report this figure(13.7)Net income, Q1 FY2024, three months to 2024-03-31−$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(17.6)Net income, Q2 FY2024, three months to 2024-06-30−$17.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(25.2)Net income, Q3 FY2024, three months to 2024-09-30−$25.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(28.4)Net income, Q4 FY2024, three months to 2024-12-31−$28.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(29.5)Net income, Q1 FY2025, three months to 2025-03-31−$29.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(31.6)Net income, Q2 FY2025, three months to 2025-06-30−$31.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(36.8)Net income, Q3 FY2025, three months to 2025-09-30−$36.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure(64.4)Net income, Q4 FY2025, three months to 2025-12-31−$64.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(40.8)Net income, Q1 FY2026, three months to 2026-03-31−$40.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(50.2)Net income, Q2 FY2026, three months to 2026-06-30−$50.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Diluted EPS$ per share(3.78)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$3.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figurenot reported(0.54)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure(0.51)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure(0.74)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figurenot reported(0.82)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(0.88)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(0.97)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figurenot reported(0.85)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(0.90)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Basic EPS$ per share(3.78)Basic EPS, Q3 FY2023, three months to 2023-09-30−$3.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figurenot reported(0.54)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure(0.51)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure(0.74)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figurenot reported(0.82)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(0.88)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.88 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure(0.97)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.97 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figurenot reported(0.85)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(0.90)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure

Balance sheet

Cash and equivalents$110.5m, Q2 FY2026
Shareholders' equity$1.17bn, Q2 FY2026
Dianthus Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m157Cash and equivalents, Q3 FY2023, at 2023-09-30$157.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure132Cash and equivalents, FY2023, at 2023-12-31$132.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-11, accession 0000950170-25-037131.Report this figure330Cash and equivalents, Q1 FY2024, at 2024-03-31$329.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure314Cash and equivalents, Q2 FY2024, at 2024-06-30$314.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure33.7Cash and equivalents, Q3 FY2024, at 2024-09-30$33.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure22.8Cash and equivalents, FY2024, at 2024-12-31$22.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure10.1Cash and equivalents, Q1 FY2025, at 2025-03-31$10.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure13.2Cash and equivalents, Q2 FY2025, at 2025-06-30$13.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure56.0Cash and equivalents, Q3 FY2025, at 2025-09-30$56.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure51.1Cash and equivalents, FY2025, at 2025-12-31$51.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure628Cash and equivalents, Q1 FY2026, at 2026-03-31$627.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure111Cash and equivalents, Q2 FY2026, at 2026-06-30$110.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Current assets$m191Current assets, Q3 FY2023, at 2023-09-30$191.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure177Current assets, FY2023, at 2023-12-31$177.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037131.Report this figure381Current assets, Q1 FY2024, at 2024-03-31$380.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057022.Report this figure366Current assets, Q2 FY2024, at 2024-06-30$365.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093948.Report this figure287Current assets, Q3 FY2024, at 2024-09-30$287.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure281Current assets, FY2024, at 2024-12-31$280.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure271Current assets, Q1 FY2025, at 2025-03-31$271.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure264Current assets, Q2 FY2025, at 2025-06-30$263.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure414Current assets, Q3 FY2025, at 2025-09-30$413.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure409Current assets, FY2025, at 2025-12-31$409.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure1,120Current assets, Q1 FY2026, at 2026-03-31$1.12bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure898Current assets, Q2 FY2026, at 2026-06-30$897.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Total assets$m192Total assets, Q3 FY2023, at 2023-09-30$192.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure179Total assets, FY2023, at 2023-12-31$179.4m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-11, accession 0000950170-25-037131.Report this figure382Total assets, Q1 FY2024, at 2024-03-31$382.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-057022.Report this figure369Total assets, Q2 FY2024, at 2024-06-30$369.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-093948.Report this figure354Total assets, Q3 FY2024, at 2024-09-30$354.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure374Total assets, FY2024, at 2024-12-31$374.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure349Total assets, Q1 FY2025, at 2025-03-31$348.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure326Total assets, Q2 FY2025, at 2025-06-30$326.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure577Total assets, Q3 FY2025, at 2025-09-30$577.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure531Total assets, FY2025, at 2025-12-31$530.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure1,247Total assets, Q1 FY2026, at 2026-03-31$1.25bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure1,213Total assets, Q2 FY2026, at 2026-06-30$1.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Current liabilities$m13.1Current liabilities, Q3 FY2023, at 2023-09-30$13.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure9.6Current liabilities, FY2023, at 2023-12-31$9.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-11, accession 0000950170-25-037131.Report this figure9.0Current liabilities, Q1 FY2024, at 2024-03-31$9.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057022.Report this figure10.0Current liabilities, Q2 FY2024, at 2024-06-30$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093948.Report this figure15.7Current liabilities, Q3 FY2024, at 2024-09-30$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure18.5Current liabilities, FY2024, at 2024-12-31$18.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure17.0Current liabilities, Q1 FY2025, at 2025-03-31$17.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure20.1Current liabilities, Q2 FY2025, at 2025-06-30$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure23.9Current liabilities, Q3 FY2025, at 2025-09-30$23.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure30.7Current liabilities, FY2025, at 2025-12-31$30.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure38.3Current liabilities, Q1 FY2026, at 2026-03-31$38.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure34.4Current liabilities, Q2 FY2026, at 2026-06-30$34.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Total liabilities$m14.1Total liabilities, Q3 FY2023, at 2023-09-30$14.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure10.5Total liabilities, FY2023, at 2023-12-31$10.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-11, accession 0000950170-25-037131.Report this figure9.8Total liabilities, Q1 FY2024, at 2024-03-31$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-057022.Report this figure10.7Total liabilities, Q2 FY2024, at 2024-06-30$10.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-093948.Report this figure16.4Total liabilities, Q3 FY2024, at 2024-09-30$16.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure21.5Total liabilities, FY2024, at 2024-12-31$21.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure20.0Total liabilities, Q1 FY2025, at 2025-03-31$20.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure23.0Total liabilities, Q2 FY2025, at 2025-06-30$23.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure31.0Total liabilities, Q3 FY2025, at 2025-09-30$31.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure37.5Total liabilities, FY2025, at 2025-12-31$37.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure45.6Total liabilities, Q1 FY2026, at 2026-03-31$45.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure41.2Total liabilities, Q2 FY2026, at 2026-06-30$41.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure
Shareholders' equity$m178Shareholders' equity, Q3 FY2023, at 2023-09-30$178.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure169Shareholders' equity, FY2023, at 2023-12-31$168.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-09, accession 0001690585-26-000006.Report this figure373Shareholders' equity, Q1 FY2024, at 2024-03-31$372.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure358Shareholders' equity, Q2 FY2024, at 2024-06-30$358.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure338Shareholders' equity, Q3 FY2024, at 2024-09-30$337.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure352Shareholders' equity, FY2024, at 2024-12-31$352.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure329Shareholders' equity, Q1 FY2025, at 2025-03-31$328.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure303Shareholders' equity, Q2 FY2025, at 2025-06-30$303.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure546Shareholders' equity, Q3 FY2025, at 2025-09-30$546.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure493Shareholders' equity, FY2025, at 2025-12-31$493.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure1,201Shareholders' equity, Q1 FY2026, at 2026-03-31$1.20bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure1,172Shareholders' equity, Q2 FY2026, at 2026-06-30$1.17bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure

Cash flow

Operating cash flow−$49.0m, Q2 FY2026
Dianthus Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(10.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123285. Derived: 9-month figure less the 6-month figure.Report this figure(11.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$11.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-11, accession 0000950170-25-037131. Derived: 12-month figure less the 9-month figure.Report this figure(14.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$14.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure(14.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$14.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0000950170-25-105030. Derived: 6-month figure less the 3-month figure.Report this figure(21.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$21.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266920. Derived: 9-month figure less the 6-month figure.Report this figure(27.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$27.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(27.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$27.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(23.9)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$23.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001690585-26-000034. Derived: 6-month figure less the 3-month figure.Report this figure(30.6)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$30.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266920. Derived: 9-month figure less the 6-month figure.Report this figure(47.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$47.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-09, accession 0001690585-26-000006. Derived: 12-month figure less the 9-month figure.Report this figure(28.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$28.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure(49.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$49.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001690585-26-000034. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)56.03m, Q2 FY2026
Dianthus Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.9Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30874,327 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062070.Report this figure0.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31874,709 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-057022.Report this figure0.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30874,900 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-093948.Report this figure3.9Diluted shares (weighted), Q3 FY2023, three months to 2023-09-303,906,886 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123285.Report this figure25.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3125,665,475 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0000950170-25-069226.Report this figure34.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3034,227,038 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0000950170-25-105030.Report this figure34.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3034,236,728 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure35.8Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3135,790,700 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure35.8Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3035,822,308 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure37.8Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3037,794,088 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001193125-25-266920.Report this figure48.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3148,032,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001690585-26-000022.Report this figure56.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3056,029,124 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure

Shares outstanding: 55.93mShares outstanding, period not labelled, at 2026-08-0355,934,378 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-04, accession 0001690585-26-000034.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.